Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.56 |
| ▸ | RB1 | P06400 | 4/20 | 0.51 |
| ▸ | HTR3A | P46098 | 3/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450266 | 1.00 | PARP1 (0.56) | PARP1RB1HTR3ACACNA1GKMT2A | |
| SCHEMBL5463493 | 0.93 | PARP1 (0.55) | PARP1RB1KMT2ATP53CASP1 | |
| SCHEMBL5458972 | 0.88 | PARP1 (0.52) | PARP1RB1HTR3AKMT2AMAPT | |
| SCHEMBL5468198 | 0.85 | RB1 (0.53) | RB1KMT2ATP53CASP1MAPT | |
| SCHEMBL5451949 | 0.85 | RB1 (0.56) | RB1KMT2ATP53CASP1MAPT | |
| SCHEMBL5456566 | 0.85 | RB1 (0.56) | RB1KMT2ATP53CASP1MAPT | |
| SCHEMBL5452894 | 0.85 | MAPK1 (0.51) | PARP1RB1KMT2AMAPT | |
| SCHEMBL5449883 | 0.85 | RB1 (0.61) | RB1KMT2ATP53CASP1MAPT | |
| SCHEMBL5456919 | 0.85 | PARP1 (0.52) | PARP1RB1TP53CASP1MAPT | |
| SCHEMBL5468069 | 0.84 | RB1 (0.55) | RB1KMT2ATP53CASP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | PARP1 709/4885RB1 1821/4885HTR3A 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.